Delving into the Latest Updates on CA111 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

CA111

Target

GIPR x GLP-1R

Action

agonists

Mechanism

GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Overweight

Inactive Indication-

Originator Organization

Chongqing Chenan Biopharmaceutical Co., Ltd.

Active Organization

Chongqing Chenan Biopharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估CA111注射液在中国健康成年男性试验参与者中单次给药的安全性、耐受性。次要目的：评估CA111注射液在中国健康成年男性试验参与者中单次给药的药代动力学（PK）特征；评估CA111注射液在中国健康成年男性试验参与者中单次给药的药效学（PD）特征；评估CA111注射液在中国健康成年男性试验参与者中单次给药的免疫原性特征。探索性目的：初步评价CA111注射液在中国健康成年男性试验参与者中单次给药后的血药浓度与QTc间期的关系。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single-dose CA111 injection in healthy adult male participants in China. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of a single-dose CA111 injection in healthy adult male participants in China; to evaluate the pharmacodynamic (PD) characteristics of a single-dose CA111 injection in healthy adult male participants in China; to evaluate the immunogenicity of a single-dose CA111 injection in healthy adult male participants in China. Exploratory objective: To preliminarily evaluate the relationship between plasma concentration and QTc interval after a single-dose CA111 injection in healthy adult male participants in China.

Start Date07 Jan 2026

Sponsor / Collaborator

Chongqing Chenan Biopharmaceutical Co., Ltd.

100 Clinical Results associated with CA111

Login to view more data

100 Translational Medicine associated with CA111

Login to view more data

100 Patents (Medical) associated with CA111

Login to view more data

100 Deals associated with CA111

Login to view more data